Neostigmina Braun (Neostigmine Methylsulfate)

Neostigmine, the active ingredient in Neostigmina Braun, is a cholinesterase inhibitor presented as a sterile solution for intramuscular, intravenous, subcutaneous use. It is used to treat myasthenia gravis, reverse non‑depolarizing neuromuscular blockade, and manage post‑operative ileus. GNH USA supplies Neostigmina Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neostigmine is an anticholinesterase that acts on neuromuscular transmission disorders. - Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction. - Reversal of non‑depolarizing neuromuscular blockade: restores normal muscle function after surgery. - Post‑operative ileus: stimulates gastrointestinal motility to alleviate bowel paralysis.

Neostigmine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis. - Diarrhea: increased bowel movements. - Abdominal cramps: discomfort in the abdomen. - Increased salivation: excess oral secretions. - Sweating: heightened perspiration.

Serious or Rare Side Effects: - Bradycardia: significant slowing of heart rate. - Bronchospasm: narrowing of airway passages. - Muscle fasciculations: involuntary muscle twitches. - Seizures: rare convulsive episodes. - Hyperkalemia: elevated blood potassium levels. - Anaphylaxis: severe allergic reaction requiring immediate medical attention.

Neostigmine requires careful monitoring due to its pharmacologic potency. - Cardiac monitoring: observe for bradycardia or arrhythmias. - Respiratory assessment: watch for bronchospasm or increased secretions. - Renal function: adjust use in patients with impaired clearance. - Gastrointestinal status: avoid in active peptic ulcer disease. - Concomitant cholinergic drugs: assess for additive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Neostigmine can interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may exacerbate bradycardia. - Anticholinergic agents: opposite pharmacologic actions reduce effectiveness. - Succinylcholine: risk of prolonged neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Cardiac glycosides: potential for increased vagal tone. - Diuretics: may worsen hypokalemia. - Anesthetic agents: monitor for additive respiratory effects.